Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2013
10/03/2013WO2013147216A1 (2-heteroarylamino)succinic acid derivative
10/03/2013WO2013147215A1 4-alkanoylamino-3-pyrazolone derivative
10/03/2013WO2013147214A1 5-hydroxypyrimidine-4-carboxamide derivative
10/03/2013WO2013147183A1 Triazinone compound and t-type calcium channel inhibitor
10/03/2013WO2013147161A1 Nipecotic acid derivative and use thereof for medical purposes
10/03/2013WO2013147160A1 Cyclic amine derivative and use thereof for medical purposes
10/03/2013WO2013147140A1 Nucleic acid molecule capable of inhibiting expression of periostin gene, method for inhibiting expression of periostin gene, and use of said nucleic acid molecule
10/03/2013WO2013147137A1 Therapeutic agent for cardiac failure
10/03/2013WO2013147135A1 Controlled-release pharmaceutical composition
10/03/2013WO2013147134A1 Mirabegron-containing pharmaceutical composition
10/03/2013WO2013147117A1 Fused azole derivative
10/03/2013WO2013147072A1 Cocrystal of 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexen-1-one
10/03/2013WO2013147026A1 Aromatic ring compound
10/03/2013WO2013147000A1 Aqueous composition containing 2-amino-3-(4-bromobenzoyl)- phenylacetic acid
10/03/2013WO2013146970A1 Novel quinoline derivative
10/03/2013WO2013146969A1 Novel disubstituted cyclohexane derivative
10/03/2013WO2013146963A1 Heterocyclic compound
10/03/2013WO2013146943A1 Anti-aging agent containing arctigenin derivative
10/03/2013WO2013146913A1 Hdc activation inhibitor, hdc activation inhibition composition, antipruritic agent, and antipruritic agent composition
10/03/2013WO2013146911A1 Prophylactic or therapeutic agent for diabetes
10/03/2013WO2013146833A1 SALT OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE
10/03/2013WO2013146797A1 Heparan sulfate production promoter
10/03/2013WO2013146754A1 Aromatic heterocyclic five-membered ring derivative having trpv4 inhibitory activity
10/03/2013WO2013146734A1 Anticancer agent
10/03/2013WO2013146687A1 Composition comprising s-adenosylmethionine and/or salt thereof
10/03/2013WO2013146649A1 Diquafosol-containing eye drop
10/03/2013WO2013146539A1 Ppars agonist activity enhancing drug
10/03/2013WO2013146437A1 3-decenoic acid derivative and use for same
10/03/2013WO2013146435A1 Agent for preventing or treating giant cell tumor or chondrosarcoma arising in bone/soft tissue
10/03/2013WO2013146386A1 Sustained-release local anesthetic preparation
10/03/2013WO2013146380A1 Coating composition and medical device
10/03/2013WO2013146376A1 Coating composition and medical device
10/03/2013WO2013146018A1 Composition, and external preparation for the skin or functional food each containing said composition
10/03/2013WO2013145750A1 Capsule pharmaceutical preparation
10/03/2013WO2013145749A1 Capsule preparation
10/03/2013WO2013144971A1 New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
10/03/2013WO2013144923A1 Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
10/03/2013WO2013144916A1 Tranilast compositions and cocrystals
10/03/2013WO2013144895A1 Otic pharmaceutical composition
10/03/2013WO2013144894A1 Nucleoside analogue as an anticancer compound
10/03/2013WO2013144867A1 Pharmaceutical formulations comprising chondroitin sulfate and hyaluronic acid derivatives
10/03/2013WO2013144860A1 A therapeutic agent for treatment of blood vessels
10/03/2013WO2013144814A1 Stable ready-to-use pharmaceutical composition of pemetrexed
10/03/2013WO2013144632A1 Treatment of proliferative diseases with pyrimidodiazepinones
10/03/2013WO2013144563A1 Treatment of acute inflammation in the respiratory tract
10/03/2013WO2013144532A1 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
10/03/2013WO2013144397A1 Cinacalcet and neuroblastic tumours
10/03/2013WO2013144356A1 Steroid, in particular a progestin, comicronized with a polymer having the pyrrolidone group, and compositions and uses
10/03/2013WO2013144339A1 Fgfr inhibitor for use in the treatment of hypophosphatemic disorders
10/03/2013WO2013144289A1 Vesicular formulations
10/03/2013WO2013144249A1 Pharmaceutical diagnostic
10/03/2013WO2013144221A1 Clear liquid carotenoid formulations and clear beverages containing them
10/03/2013WO2013144193A1 Combination therapy for treating hcv infection in specific patient subgenotype sub-population
10/03/2013WO2013144191A1 Substituted 2-amino-3-cyanopyridines as inhibitors of sodium-calcium exchange and use thereof for cardiovascular diseases
10/03/2013WO2013144189A1 Amino-substituted imidazopyridazines
10/03/2013WO2013144180A1 Heteroaryl compounds with cyclic bridging unit for use in the treatment helminth infection
10/03/2013WO2013144179A1 Heteroaryl compounds with a-cyclic bridging unit
10/03/2013WO2013144176A1 Controlled release formulatin comprising mesalamine
10/03/2013WO2013144172A1 Novel pyrazolopyrimidines
10/03/2013WO2013144154A1 Functionalized porous silicon nanoparticles and use thereof in photodynamic therapy
10/03/2013WO2013144147A1 Fungicide formulations for plasticized pvc
10/03/2013WO2013144145A1 Stable compositions of thiabendazole and iodine-containing fungicides
10/03/2013WO2013144129A1 Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
10/03/2013WO2013144119A1 Potent synergistic effect of doxycycline with fluconazole against candida albicans
10/03/2013WO2013144098A1 New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists
10/03/2013WO2013144097A1 New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists
10/03/2013WO2013144085A1 4-oxo-2-pentenoic acid and liver disorders
10/03/2013WO2013144083A1 4-oxo-2-pentenoic acid and the health of the digestive tract
10/03/2013WO2013144080A1 4-oxo-2-pentenoic acid and cardiovascular health
10/03/2013WO2013144079A1 4-oxo-2-pentenoic acid and skin pigmentation
10/03/2013WO2013144077A1 4-oxo-2-pentenoic acid and brain health
10/03/2013WO2013143891A1 Nicotine formulation
10/03/2013WO2013143688A1 Taste-masked ibuprofen granules
10/03/2013WO2013143663A1 Bicyclic pyrazinone derivatives
10/03/2013WO2013143597A1 Demethylase enzymes inhibitors
10/03/2013WO2013143581A1 Combination therapy for treating hcv infection in specific patient subgenotype sub-population
10/03/2013WO2013143548A1 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
10/03/2013WO2013143477A1 1,4-dihydroxy-6-methyl-2-pyridone compound, and preparation method and application thereof
10/03/2013WO2013143466A1 Substituted pyrimidine derivative as aurora kinase inhibitor
10/03/2013WO2013143462A1 Blood displacement foundation liquid and preparation method thereof
10/03/2013WO2013143376A1 Quinoline compounds containing 1,2,4-triazine-3,5-dione and use thereof
10/03/2013WO2013143319A1 Quinazoline derivative and usage thereof
10/03/2013WO2013143300A1 Sustained-release preparation of fulvestrant or derivatives thereof and preparation method therefor
10/03/2013WO2013143299A1 Lactate-based fulvestrant or fulvestrant derivative oily preparation and preparation method thereof
10/03/2013WO2013143298A1 Fulvestrant or fulvestrant derivative oily preparation and preparation method thereof
10/03/2013WO2013143259A1 Phosphodiesterase-4 inhibitor capable of avoiding vomit reaction and preparation method for same
10/03/2013WO2013143184A1 Streptomyces, and anti-tumor compounds spiro-indimycin a-d and preparation method and application thereof
10/03/2013WO2013143057A1 Quinazoline derivative and application thereof
10/03/2013WO2013143000A1 Combination therapy for the treatment of cancer
10/03/2013WO2013142935A1 Combretastatin derivatives, pharmaceutical compositions comprising same and use of these derivatives as anti-tumour agents
10/03/2013WO2013142912A1 Methods and compositions for reducing ocular discomfort
10/03/2013WO2013117744A9 Methods of treating fibrosis
10/03/2013WO2013117503A3 Pi3k inhibitors for treating fibrotic diseases
10/03/2013WO2013116713A9 Treating neuropathic pain with seh inhibitors
10/03/2013WO2013114403A8 Substituted 4,5-dihydro-2h-benzo[e]indazole-9-carboxylates for the treatment of diabetes and related disorders
10/03/2013WO2013114339A4 Combination therapy for cancer using hsp27 inhibitor and egfr tyrosine kinase inhibitors or anti-folates
10/03/2013WO2013102919A4 Polymorphic forms of ivabradine hydrochloride
10/03/2013WO2013100660A3 Pharmaceutical composition for treatment of eye pain, containing pge2 synthesis inhibitor
10/03/2013WO2013088452A3 Quinoline derivatives as renin inhibitors
10/03/2013WO2013077921A3 Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
1 ... 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 ... 7860